Value Proposition

Innovative R&D Drives Business Sustainability

Why Invest?

Pilatus Biosciences offers a unique opportunity to invest early at an attractive valuation. Our innovative therapies are already drawing strong interest from global pharmaceutical leaders, positioning us for high-value licensing deals or early M&A exits. In today’s selective market, Pilatus stands out through scientific innovation, capital efficiency, and a clear path to value creation.

Investment Highlights

01. About Us

Pilatus Biosciences is a preclinical-stage biotech company pioneering first-in-class biologics targeting metabolic checkpoints to reprogram the tumor microenvironment (TME)

02. Novel Science

Differentiated Immunometabolism approach targeting growing Cancer Immunotherapy and Metabolic Disease market

03. Lead Pipeline: PLT012

PLT012, a humanized anti-CD36 antibody, has demonstrated preclinical efficacy and received FDA Orphan Drug Designation for Liver cancers.

04. Funding Status & Exit Strategy

Seeking $ 10 million in Series Pre-A Round financing and early exit opportunities through M&A or IPO by 2027, targeting a valuation exceeding $800M.

Connect with us